Global healthcare stocks fell Friday, hit by a rout that reached Europe and Asia and spread across sectors after hammering AI trades and U.S. markets earlier in the week.
Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target’s closing price as of Friday.
The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
Login
